Abbelight Secures Series B Funding to Accelerate Innovation in Super-Resolution Microscopy
Abbelight, a global pioneer in end-to-end super-resolution microscopy solutions, today announced the successful completion of a Series B financing round led by AVANT BIO, a growth equity firm specializing in technologies shaping the future of therapeutic discovery and development. The new funding marks a significant milestone in Abbelight’s growth and will support its continued innovation, market expansion, and adoption across the broader life sciences ecosystem.Founded in 2016, Abbelight has spent nearly a decade transforming how researchers visualize and analyze biological systems at the nanoscale. The company has established itself as a technology leader by delivering integrated microscopy and nanoscopy (SMLM) solutions that combine advanced chemistry, optics, and data analytics to unlock unprecedented insights into complex intracellular mechanisms.
With ten years of experience in the life sciences research market, Abbelight has fundamentally changed the way scientists see, quantify, and interpret biological processes,” said Nicolas Bourg, Chief Technology Officer and co-founder of Abbelight. “This funding comes at the perfect time to refine and expand our groundbreaking imaging toolbox to address emerging and high-impact verticals, such as single-cell phenotyping and mechanism-of-effect validation in drug discovery.”
Advancing Nanoscale Discovery
Great things are happening at the nanoscale—and Abbelight is enabling researchers to observe biological structures like never before,” said Daniella Kranjac, Founding General Partner of AVANT BIO. “The company’s breakthroughs in super-resolution microscopy and its integrated workflows represent exactly the kind of enabling technologies that accelerate scientific discovery and foster innovation across the life sciences
The Series B investment will allow Abbelight to scale its commercial operations, enhance customer support, and further expand its presence in key markets worldwide. The company already serves a growing and established customer base, supported by a team of approximately 60 employees.
This is an exciting moment for Abbelight,” said Jean-Baptiste Marie, Chief Executive Officer and co-founder. This funding accelerates our commercial expansion and allows us to continue delivering top-tier support to our customers. AVANT BIO’s partnership will be instrumental in driving broader adoption of our solutions across the bioindustry, including biopharma, biotech companies, and contract research organizations.”
By expanding into new application areas and strengthening its engagement with industry partners, Abbelight aims to play a critical role in advancing next-generation therapeutic research and development.
Founded in 2016, Abbelight is a rapidly growing life sciences company specializing in super-resolution microscopy and nanoscopy (SMLM) solutions. Its comprehensive portfolio integrates cutting-edge chemistry, optics, and data analytics, enabling researchers at public research institutions and biotech companies to explore and understand complex biological interactions at the nanoscale. Driven by innovation and customer collaboration, Abbelight is committed to delivering high-impact imaging solutions and world-class support to its global customer base.
For more information, visit www.abbelight.com.
About AVANT BIO
AVANT BIO is a growth equity firm focused on key technologies that are shaping how tomorrow’s therapeutics are discovered, developed, and manufactured. The firm invests across multiple stages of company development, with a mission to accelerate growth, unlock value, and support innovation across therapeutic technologies, TechBio, and HealthTech.
Learn more at www.avant.bio and follow AVANT BIO on LinkedIn for industry insights and updates.
